NEW YORK and NEW ORLEANS, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into iRhythm Technologies, Inc. (NasdaqGS: IRTC). On May 30, 2023, the Company disclosed the receipt of a Warning Letter from the FDA regarding “non-conformities to regulations for medical devices, including medical device reporting requirements, relating to the Company’s Zio ...

分析师评级与目标价 - Needham维持波士顿科学公司买入评级 目标股价121美元 [1] - 评级基于公司计划在2025年底推出用于外周血管的Bolt激光血管内碎石系统 [1] 新产品与技术优势 - Bolt系统相比Shockwave Medical的IVL系统具有更好的输送性 更多脉冲和更可靠的目标声波治疗 [3] - 公司已开始进行骨折研究以评估IVL技术的临床应用 [2] - 外周介入和介入心脏病学产品组合及销售团队将助力快速获取IVL市场份额 [3] 市场机会与财务影响 - IVL市场存在85亿美元的市场机会 [2] - IVL技术预计在未来五年为收入增长贡献0.3% 为每股收益增长贡献0.5% [3] 公司背景 - 波士顿科学是全球医疗技术公司 专注于开发销售微创医疗设备以改善患者治疗效果并降低医疗成本 [4]

分析师评级与价格目标 - Bernstein SocGen Group重申对Intuitive Surgical的“跑赢大盘”评级，目标股价为685美元 [1] - 该研究机构认为公司股票在从1月份的610美元高点回落后，目前正以折价交易，当前交易区间为投资者提供了买入机会 [2] 公司业绩与产品进展 - 公司第二季度营收同比增长21%，达到24.4亿美元 [3] - 增长得益于da Vinci 5外科手术系统进入广泛推广阶段 [3] - 公司有五个变革性产品即将发布，这些发布预计将增强市场对该公司股票的情绪 [3] 公司业务概览 - Intuitive Surgical开发并销售da Vinci机器人辅助外科手术系统，该技术旨在通过增强精度、视野和控制力，使外科医生能够进行微创手术 [4] - 公司的目标是使手术对患者更有效且创伤更小 [4]

Key Takeaways SYK partners with Siemens Healthineers to co-develop a robotic neurovascular system.The collaboration integrates robotics, imaging and SYK devices for faster care.SYK aims to enhance workflows, precision and patient outcomes in neurovascular procedures.Stryker (SYK) recently entered into a strategic partnership with Siemens Healthineers to co-develop a first-of-its-kind robotic system for neurovascular procedures. The collaboration is designed to integrate robotics, imaging and Stryker’s neuro ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. DXCM, citing that the company sold the "adulterated" device.Benzinga reached out to DexCom for comments and is yet to hear from them.A surprise FDA inspection found Dexcom made an unauthorized design change to the G7 glucose monitoring device, with internal tests showing worse accuracy across the board.Despite this, the company sold the device, drawing FDA scrutiny. Executives have since departed as patient complaints climbed, rivals ...

We recently published All-Time Rush: 8 of 10 Big Names Hit Fresh Record Highs. Hologic Inc. (NASDAQ:HOLX) is one of the best performers on Wednesday. Shares of Hologic Inc. rallied by 7.69 percent on Wednesday to close at $68.20 as investors repositioned portfolios amid reports that it was again in talks with two investment companies for a potential sale. According to a report by Bloomberg, Hologic Inc. (NASDAQ:HOLX) has received a new acquisition offer from Blackstone Inc. and TPG Inc. after earlier neg ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Inspire Medical Systems, Inc. stands tenth among them. Inspire Medical Systems, Inc. (NYSE:INSP), a leader in minimally invasive devices for obstructive sleep apnea (OSA), reported challenges in the commercial rollout of its new Inspire V system. Delays in onboarding treatment centers and navigating reimbursement processes have slowed full patient adoption, with some patients still using the older Inspire I ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Integer Holdings Corporation (NYSE:ITGR), a global contract development and manufacturing organization specializing in medical devices, reported solid growth in 2025. Q2 sales rose 11% to $476 million, driven by new product launches in the electrophysiology and neurovascular markets. The Cardio & Vascular segment led the surge with 24% growth, while the Cardiac Rhythm & Neuromodulation segment saw modest ga ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Haemonetics Corporation is one of them. Haemonetics Corporation (NYSE:HAE), a global leader in blood and plasma management technologies, continues to advance healthcare efficiency through innovative medical devices. In 2025, the company launched the PerQseal Elite vascular closure system, receiving European CE Mark approval. This fully bioresorbable, sutureless device is designed for large-bore vascular ac ...

公司国际扩张战略 - 国际扩张是公司增长战略的关键部分 但面临中国经营环境困难和非洲HIV检测业务资金削减的宏观风险[1] - 国际诊断业务预计持续承压至2025年 但国际市场将在2026年及以后对整体增长做出重要贡献[1] - 公司国际业务预计在2025至2027财年以4.7%的复合年增长率扩张[4] 妇科手术业务表现 - 妇科手术部门受益于商业和市场准入能力的强劲投资 微创产品覆盖范围扩大[2] - 2025财年第三季度国际手术业务增长近25% 得益于产品组合势头和新纳入报销市场的强劲接受度[2] - NovaSure在国内销售下降情况下在海外持续实现两位数增长 Gynesonics有望成为重要国际增长动力[2] 诊断平台与产品进展 - BV/CV/TV分子诊断检测已成为全球第二大产品 在性传播感染检测领域存在重大全球份额提升机会[3] - Panther平台全球使用率达到历史新高 Genius数字诊断系统全球推广获得强烈反馈[3][8] - 虽然在美国3D乳腺摄影市场占有近85%份额 但全球市场发展严重不足 呈现重大机遇[3] 同业公司动态 - 雅培2025年第二季度国际销售额增长6.6% Navitor经导管主动脉瓣植入系统获得CE标志扩展认证[5] - 赛默飞世尔从国际市场获得大量收入 近期推出Olink Target 48神经退行性疾病检测面板[6] 财务表现与估值 - 过去一年公司股价下跌18.2% 行业同期下跌18.4%[7] - 公司远期三年市销率为3.57倍 低于行业平均的3.96倍 当前价值评级为B[9] - 当前季度(2025年9月)每股收益预期为1.10美元 下一财年(2026年9月)预期为4.48美元[11]